-
Mashup Score: 4New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy - 3 day(s) ago
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors - 3 day(s) ago
The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer - 3 day(s) ago
China’s NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy @RoswellPark @EbosLab #oncology #MedTwitter https://t.co/3ABsoatKSq